1-bromo-1-cyclopentanecarboxylic acid chloride | 56447-23-5

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: 1-bromo-1-cyclopentanecarboxylic acid chloride
• 英文别名: acid chloride 10g；1-Bromocyclopentanecarbonyl chloride；1-Brom-1-chlorformyl-cyclopentan；1-Bromocyclopentane-1-carbonyl chloride
• CAS: 56447-23-5
• 化学式: C₆H₈BrClO
• mdl: MFCD21602079
• 分子量: 211.486
• InChiKey: DBUSSDLMLYFONI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-bromo-1-cyclopentanecarboxylic acid chloride 在 喹啉 作用下， 反应 2.0h， 生成 环戊烯-1-羧酸甲酯
  参考文献：
  名称：

  Iridium(i)-catalyzed vinylic C–H borylation of 1-cycloalkenecarboxylates with bis(pinacolato)diboron

  摘要：

  Ir(I)催化的带有双(频哪醇)二硼的1-环烯羧酸衍生物的C-H硼化反应，以优异的产率得到各种带有功能基团的烯基�硼酸盐。该反应还用于一步法硼化/铃木-宫浦交叉偶联程序。

  DOI：

  10.1039/c3cc44149k
• 作为产物：
  描述：

  环戊酸 在 氯化亚砜 、 氢溴酸 、 溴 作用下， 以 水 为溶剂， 反应 1.0h， 生成 1-bromo-1-cyclopentanecarboxylic acid chloride
  参考文献：
  名称：

  铁催化的α-叠氮基酰胺的分子内CH胺化反应。

  摘要：

  最近，铁催化的脂肪族叠氮化物分子内CH胺化反应已成为制备氮杂环的有力工具。这篇论文报道了α-叠氮基酰胺可以通过分子内的C（sp3）-H胺化反应，由FeCl2和β-二酮配体组成的简单催化体系高效地转化为咪唑啉酮化合物。该反应为多取代的咪唑啉酮提供了一种简单且原子经济的方法。

  DOI：

  10.1021/acs.orglett.8b03927

文献信息

• Caphalosporin compounds having at position-7 an .alpha.-etherified
  申请人：Glaxo Operations UK Limited

  公开号：US04208517A1

  公开（公告）日：1980-06-17

  Antibiotic compounds of the general formula ##STR1## [wherein R is a phenyl, thienyl or furyl group; R.sup.a and R.sup.b, which may be the same or different, are each selected from hydrogen, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.3-7 cycloalkyl, phenyl, naphthyl, thienyl, furyl, carboxy, C.sub.2-5 alkoxycarbonyl and cyano, or R.sup.a and R.sup.b together wth the carbon atom to which they are attached form a C.sub.3-7 cycloalkylidene or cycloalkenylidene group; R.sup.c and R.sup.d, which may be the same or different, each represents a hydrogen atom or a substituting group e.g. an alkyl group or substituted alkyl group; or R.sup.c and R.sup.d together with the nitrogen atom to which they are attached form a saturated or unsaturated heterocyclic ring which contains 5-7 ring members and which may contain additional hetero atoms, and may be substituted by lower alkyl; R.sup.e represents hydrogen or C.sub.1-4 alkyl; m and n are each 0 or 1 such that the sum of m and n is 0 or 1 and Y is selected from various oxygen and sulphur nucleophiles] and non-toxic derivatives thereof.

  通用公式##STR1##的抗生素化合物[其中R是苯基、噻吩基或呋喃基；R.sup.a和R.sup.b，可以相同也可以不同，分别选自氢、C.sub.1-4烷基、C.sub.2-4烯基、C.sub.3-7环烷基、苯基、萘基、噻吩基、呋喃基、羧基、C.sub.2-5烷氧羰基和氰基，或者R.sup.a和R.sup.b与它们连接的碳原子一起形成C.sub.3-7环烷基亚甲基或环烯基亚甲基；R.sup.c和R.sup.d，可以相同也可以不同，分别代表氢原子或取代基，例如烷基或取代烷基；或者R.sup.c和R.sup.d与它们连接的氮原子一起形成含有5-7个环成员的饱和或不饱和杂环，可能含有额外的杂原子，并且可能被低烷基取代；R.sup.e代表氢或C.sub.1-4烷基；m和n分别为0或1，使m和n的和为0或1，Y选自各种氧和硫亲核试剂]及其无毒衍生物。
• 6-(Substituted-cycloalkylcarboxamide) penicillanic acids
  申请人：Bayer Aktiengesellschaft

  公开号：US03954730A1

  公开（公告）日：1976-05-04

  Penicillins of the formula ##SPC1## Or a pharmaceutically-acceptable, nontoxic salt thereof, Wherein R.sub.1 and R.sub.2 are the same or different and each is hydrogen, fluorine, chlorine or bromine; or when R.sub.2 is hydrogen, R.sub.1 can also be cyano, hydroxyl, azido, amino or nitro; or R.sub.1 and R.sub.2 are bonded to a ring carbon atom and constitute a single oxygen atom; R.sub.3 is hydrogen, methyl, chlorine, bromine, cyano, methoxy or carboxyl; and n is 2 to 7; Are useful for their antibacterial activity.

  盐酸盐或药用可接受的非毒性盐的公式为##SPC1##的青霉素，其中R.sub.1和R.sub.2相同或不同，每个都是氢、氟、氯或溴；或者当R.sub.2是氢时，R.sub.1也可以是氰基、羟基、叠氮基、氨基或硝基；或者R.sub.1和R.sub.2连接到一个环碳原子并构成一个单氧原子；R.sub.3是氢、甲基、氯、溴、氰基、甲氧基或羧基；n为2到7；它们因其抗菌活性而有用。
• METHOD FOR PRODUCING ALPHA-HALOGENOACETOPHENON COMPOUND, AND ALPHA-BROMOACETOPHENON COMPOUND
  申请人：FUJIFILM Corporation

  公开号：US20160200654A1

  公开（公告）日：2016-07-14

  A method for producing an α-halogenoacetophenon compound includes reacting a specific α-halogenocarboxylic halide compound and a specific phenyl compound in the presence of a Lewis acid in a solvent, in which the α-halogenoacetophenon compound and the phenyl compound are reacted with each other in a molar ratio of the Lewis acid to the phenyl compound represented below. 2≦Lewis acid/phenyl compound≦6

  生产α-卤代乙酰苯酮化合物的方法包括在溶剂中，在Lewis酸的存在下，反应特定的α-卤代羧酸卤化物化合物和特定的苯化合物，其中α-卤代乙酰苯酮化合物和苯化合物按照以下所示的Lewis酸与苯化合物的摩尔比进行反应。2≦Lewis酸/苯化合物≦6
• Selective Fluoromethyl Couplings of Alkynes via Nickel Catalysis
  作者：Huan Li、Fang Wang、Shengqing Zhu、Lingling Chu

  DOI：10.1002/anie.202116725

  日期：2022.2.21

  A nickel-catalyzed three-component carbo-fluoromethylation of alkynes with aliphatic halides and BrCF2H or ICH2F in the presence of zinc is described. This process is based on a nickel-mediated radical addition/fluoromethyl coupling domino strategy and provides selective access to a diverse range of biologically valuable CF2H- and CH2F-substituted alkenes with excellent regio- and stereoselectivity

  描述了在锌存在下，炔烃与脂肪族卤化物和 BrCF 2 H 或 ICH 2 F 的镍催化三组分碳氟甲基化反应。该过程基于镍介导的自由基加成/氟甲基偶联多米诺策略，并提供对具有优异区域选择性和立体选择性的多种具有生物价值的 CF 2 H-和 CH 2 F-取代烯烃的选择性访问。
• BICYCLIC HETEROCYCLIC DERIVATIVE
  申请人：Nakahira Hiroyuki

  公开号：US20110190278A1

  公开（公告）日：2011-08-04

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R 1a is halogen, etc.; R 1m is H, etc.; G 1 is —N(R 1b )—, etc.; G 2 is —CO—, etc.; G 3 is —C(R 1c )(R 1d )—, etc.; G 4 is oxygen, etc.; R 1b is optionally substituted C 1-6 alkyl, etc.; R 1c and R 1d are independently the same or different, H, etc.; R 3 is H, optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3 c and R 3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其可用作肾素抑制剂。[其中，R1a是卤素等；R1m是H等；G1是—N（R1b）—等；G2是—CO—等；G3是—C（R1c）（R1d）—等；G4是氧等；R1b是可选取代的C1-6烷基等；R1c和R1d独立选择为H等；R3是H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立选择为相同或不同的基团：-A-B（其中A是单键等，B是H等）等；n为1等。]